Tags

Type your tag names separated by a space and hit enter

Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
Aliment Pharmacol Ther 2003; 17(2):235-41AP

Abstract

BACKGROUND

: Effective intra-oesophageal acid suppression is an important therapeutic goal in complicated and atypical gastro-oesophageal reflux disease.

AIM

: To compare the efficacy of lansoprazole and pantoprazole in normalizing oesophageal acid exposure.

METHODS

: Fifty patients with complicated or atypical gastro-oesophageal reflux disease were randomly assigned to receive 30 mg lansoprazole (n = 26) or 40 mg pantoprazole (n = 24) once daily. Three to four weeks after the start of treatment, patients underwent 24-h oesophageal pH monitoring whilst on therapy. If the results were improved but still abnormal, the dosage was doubled and pH monitoring was repeated. If oesophageal acid exposure was not improved, the patient was shifted to the alternative drug regimen.

RESULTS

: Oesophageal acid exposure was normalized in all 26 patients treated with lansoprazole (in 35% of cases with a double daily dosage), whereas in six of the 24 (25%) patients treated with pantoprazole it was neither normalized nor lowered (P = 0.008). Accordingly, the mean percentage acid reflux time was significantly lower for the lansoprazole group (2.1) than for the pantoprazole group (5.8) (P = 0.032).

CONCLUSIONS

: Effective intra-oesophageal acid suppression can be accomplished more reliably with lansoprazole than with pantoprazole in patients with complicated and atypical gastro-oesophageal reflux disease.

Authors+Show Affiliations

Divisionee de Medicina Interna e Gastroenterologia, Ospedale S. Agostino, Modena, Italy. marziofrazzoni@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

12534408

Citation

Frazzoni, M, et al. "Effective Intra-oesophageal Acid Suppression in Patients With Gastro-oesophageal Reflux Disease: Lansoprazole Vs. Pantoprazole." Alimentary Pharmacology & Therapeutics, vol. 17, no. 2, 2003, pp. 235-41.
Frazzoni M, De Micheli E, Grisendi A, et al. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. Aliment Pharmacol Ther. 2003;17(2):235-41.
Frazzoni, M., De Micheli, E., Grisendi, A., & Savarino, V. (2003). Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. Alimentary Pharmacology & Therapeutics, 17(2), pp. 235-41.
Frazzoni M, et al. Effective Intra-oesophageal Acid Suppression in Patients With Gastro-oesophageal Reflux Disease: Lansoprazole Vs. Pantoprazole. Aliment Pharmacol Ther. 2003;17(2):235-41. PubMed PMID: 12534408.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. AU - Frazzoni,M, AU - De Micheli,E, AU - Grisendi,A, AU - Savarino,V, PY - 2003/1/22/pubmed PY - 2003/3/26/medline PY - 2003/1/22/entrez SP - 235 EP - 41 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 17 IS - 2 N2 - BACKGROUND: : Effective intra-oesophageal acid suppression is an important therapeutic goal in complicated and atypical gastro-oesophageal reflux disease. AIM: : To compare the efficacy of lansoprazole and pantoprazole in normalizing oesophageal acid exposure. METHODS: : Fifty patients with complicated or atypical gastro-oesophageal reflux disease were randomly assigned to receive 30 mg lansoprazole (n = 26) or 40 mg pantoprazole (n = 24) once daily. Three to four weeks after the start of treatment, patients underwent 24-h oesophageal pH monitoring whilst on therapy. If the results were improved but still abnormal, the dosage was doubled and pH monitoring was repeated. If oesophageal acid exposure was not improved, the patient was shifted to the alternative drug regimen. RESULTS: : Oesophageal acid exposure was normalized in all 26 patients treated with lansoprazole (in 35% of cases with a double daily dosage), whereas in six of the 24 (25%) patients treated with pantoprazole it was neither normalized nor lowered (P = 0.008). Accordingly, the mean percentage acid reflux time was significantly lower for the lansoprazole group (2.1) than for the pantoprazole group (5.8) (P = 0.032). CONCLUSIONS: : Effective intra-oesophageal acid suppression can be accomplished more reliably with lansoprazole than with pantoprazole in patients with complicated and atypical gastro-oesophageal reflux disease. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/12534408/Effective_intra_oesophageal_acid_suppression_in_patients_with_gastro_oesophageal_reflux_disease:_lansoprazole_vs__pantoprazole_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0269-2813&date=2003&volume=17&issue=2&spage=235 DB - PRIME DP - Unbound Medicine ER -